Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
167.88B
Market cap167.88B
Price-Earnings ratio
11.61
Price-Earnings ratio11.61
Dividend yield
3.04%
Dividend yield3.04%
Average volume
15.71M
Average volume15.71M
High today
$39.26
High today$39.26
Low today
$38.67
Low today$38.67
Open price
$39.16
Open price$39.16
Volume
572.55K
Volume572.55K
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

TipRanks 1h
Novo Nordisk announces positive top-line results from Pioneer Teens study

The company states: “Novo Nordisk (NVO) today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 dia...

The Motley Fool 3h
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Investors looking to capitalize on the rapidly growing weight-loss market face a difficult choice. Eli Lilly (LLY +2.04%) is the leader in the field, but some w...

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
Simply Wall St 19h
Is Novo Nordisk Price Weakness Creating A Potential Valuation Opportunity?

If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent performance gives you plenty to think about. The stock last...

Is Novo Nordisk Price Weakness Creating A Potential Valuation Opportunity?

Analyst ratings

63%

of 35 ratings
Buy
31.4%
Hold
62.9%
Sell
5.7%

More NVO News

Simply Wall St 1d
A Look At Hims & Hers Health Valuation After Novo Nordisk Deal And GLP 1 Market Shift

Hims & Hers Health (HIMS) is back in focus after renewing its partnership with Novo Nordisk, giving the telehealth platform access to branded weight loss drugs...

A Look At Hims & Hers Health Valuation After Novo Nordisk Deal And GLP 1 Market Shift
Barron's 2d
Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game.

Healthcare Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game. In this article LLY NVO AMZN SPX Amazon announced a ‘GLP-1 Management Pr...

Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game.
TipRanks 2d
Lilly, Novo slip after CVS opts out of Medicare obesity drug model

Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) are under pressure on Tuesday after CVS Health (CVS) announced the company’s decision regarding Medicare obesit...

Investor's Business Daily 2d
Amazon Stock: Anthropic And OpenAI Deals Highlight 'Growing Confidence' In Custom AI Chips

Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon. 3:58 AM ET Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics tumbled Tuesday after Am...

Amazon Stock: Anthropic And OpenAI Deals Highlight 'Growing Confidence' In Custom AI Chips
TipRanks 2d
Lexaria Bioscience provides update on GLP-1 oral pill market

Lexaria Bioscience (LEXX) provides an update of additional recent developments in the fast-moving glucagon-like peptide-1 oral market. The company said, ” The G...

Nasdaq 2d
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly

Key Points Novo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market. The two companies, however, can’t fend off creativ...

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Nasdaq 3d
Here's Why Agios Pharmaceuticals Crashed 23% Today

Key Points Agios Pharmaceuticals shares dropped 23% following Novo Nordisk's trial results. Novo's etavopivat outperformed Agios' mitapavit in key sickle cell...

Here's Why Agios Pharmaceuticals Crashed 23% Today

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.